Join collection
Hello, welcome to our official website!
腾讯立志成为移动互联网“连接器”
2019-01-12

马化腾公开致信合作伙伴:腾讯立志成为移动互联网“连接器”


11月1日,腾讯将在南京举办2018腾讯全球合作伙伴大会。在开幕前夕,腾讯董事会主席兼**执行官马化腾发表了《给合作伙伴的一封信》,向合作伙伴分享了关于消费互联网与产业互联网生态融合、社交与内容生态创新的思考,并提出了腾讯在移动互联网下半场的开放战略新目标。

他认为,伴随数字化进程,移动互联网的主战场,正在从上半场的消费互联网,向下半场的产业互联网方向发展。要让个人用户获得更好的产品与服务,就必须让互联网与各行各业深度融合。腾讯也非常愿意成为各行各业*好的“数字化助手”,以“去中心化”的方式帮助传统企业和公共服务机构实现数字化转型升级,

未来与企业和政府等机构客户的合作中,腾讯的业务接口将更加集中,合作规则更加清晰,资源能力更形成合力。腾讯将更充分地发挥数字化服务潜能和差异化优势:不但要能够提供基础工具和能力的“食材”;还要能快速响应个性化需求,将不同食材搭配起来“炒菜”;更要提供一整套的“宴席”——多样化、系统化、安全可控的商业解决方案(BaaS, 即Business as a Service)。

此外,马化腾也表示,腾讯也将进一步打造年轻人喜欢的社交平台与内容生态,与数字内容领域的合作伙伴建立更加紧密的新生态;借助“社交×内容”的网络效应,通过新文创的方式让更多用户和年轻人,获得高品质的数字内容消费体验,并以*先进的技术手段保护好未成年人,避免不健康的消费沉迷。

在移动互联网下半场,腾讯开放战略也将树立新目标。马化腾表示,腾讯要做好“连接器”,为各行各业进入“数字世界”提供*丰富的“数字接口”;还要做好“工具箱”,提供*完备的“数字工具”;更要做好“生态共建者”,提供云计算、大数据和人工智能等新型基础设施,激发每个参与者进行数字创新,与各行各业合作伙伴一起共建“数字生态共同体”。

“腾讯并不是要到各行各业的跑道上去赛跑争**,而是要立足做好‘助手’,帮助实体产业在各自的赛道上成长出更多的世界**。”马化腾表示。

以下为公开信全文:

各位合作伙伴,大家好!

今年是腾讯成立20年周年。我们迎来了公司历史上的第三次重大战略升级和架构调整。这个消息已经在一个月前公布。在这里,我想跟各位合作伙伴分享更多的想法。

这次调整,我们经过了将近一年的思考和酝酿。腾讯自2012年以来组建的七大事业群,目前已经重组为六大事业群。在保留原有的技术工程事业群(TEG)、微信事业群(WXG)、互动娱乐事业群(IEG)、企业发展事业群(CDG)基础上,我们整合成立了两个新的事业群:云与智慧产业事业群(CSIG)、平台与内容事业群(PCG)。同时,我们整合升级了新的广告营销服务线,并将成立腾讯技术委员会。腾讯每隔六七年就可能进行一次大的组织架构调整,以顺应外界变化带来的战略升级。今天,我们两个新成立的BG,分别承担着消费互联网与产业互联网生态融合、社交与内容生态创新的重要探索。

我们认为,移动互联网的上半场已经接近尾声,下半场的序幕正在拉开。伴随数字化进程,移动互联网的主战场,正在从上半场的消费互联网,向下半场的产业互联网方向发展。腾讯一直说专注做连接,希望连接人与人、人与物以及人与服务。我们越来越发现,除了实现人与人的连接,如果大量的“物”与“服务”不能全面数字化升级,那么“人与物、人与服务的连接”就难以迭代。要让个人用户获得更好的产品与服务,我们必须让互联网与各行各业深度融合,把数字创新下沉到生产制造的核心地带,将数字化推进到供应链的每一个环节。没有产业互联网支撑的消费互联网,只会是一个空中楼阁。

接下来,腾讯将扎根消费互联网,拥抱产业互联网。我们要继续做好“消费端”的智慧连接,更要促成“供应端”与互联网的深度融合,帮助各行各业实现数字化转型升级。对于大量的传统企业来说,要尽快打通从生产制造到消费服务的价值链,要实现从智慧零售到智能制造、从消费到产业(C2B)的生态协同,就不能仅仅满足于一个完整的传统产业链,未来更需要与互联网公司进行跨界融合,真正触达海量用户,并实现硬件、软件与服务三位一体的生态化能力。没有消费互联网助力的产业互联网,就像一条无法与大海连通的河流,可能在沙漠中日渐干涸。

腾讯服务着数以十亿计的个人用户,具有连接国内*丰富场景和互联网产品的生态服务能力,将致力于消费互联网与产业互联网的融合创新。我们非常愿意成为各行各业*好的“数字化助手”,以“去中心化”的方式帮助传统企业和公共服务机构实现数字化转型升级,让每一个产业都变身为智慧产业,实现数字化、网络化和智能化。

从2011年起,腾讯的开放战略伴随着移动互联网的高速发展而不断演进。七年时间,我们从“一棵大树”成长为“一片森林”,与合作伙伴共建了一个开放的互联网生态,可以说,我们在移动互联网上半场基本实现了开放战略的目标。接下来,我们要做好“连接器”,为各行各业进入“数字世界”提供*丰富的“数字接口”;还要做好“工具箱”,提供*完备的“数字工具”;同时我们更要做好“生态共建者”,提供云计算、大数据和人工智能等新型基础设施,激发每个参与者进行数字创新,与各行各业合作伙伴一起共建“数字生态共同体”。这是腾讯开放战略在移动互联网下半场希望实现的新目标。

产业互联网的探索,将为我们与生态伙伴提供更广阔的合作空间。我们希望,未来与企业和政府等机构客户的合作中,腾讯的业务接口更加集中,合作规则更加清晰,资源能力更能形成合力。腾讯将把数字化服务的潜能和差异化优势,更充分地发挥出来:我们不但能够根据客户的需要提供基础工具和能力作为“食材”;还能够快速响应客户的个性化需求,将不同食材搭配起来“炒菜”;更重要的是,我们还能够提供一整套的“宴席”——多样化、系统化、安全可控的商业解决方案(BaaS, 即Business as a Service)。这不单单能够帮客户节省成本、提**率,而且还能够帮助客户在数字化转型升级过程中,找到新的商业模式和盈利增长点。目前我们已经在医疗、教育、交通、零售和制造业等领域进行初步尝试。

与此同时,我们希望进一步打造年轻人喜欢的社交平台和内容生态,与数字内容领域的合作伙伴建立更加紧密的新生态。我们将借助“社交×内容”的网络效应,让UGC与PGC彼此滋养,形成*有活力的IP创生土壤。我们还希望与合作伙伴一起,帮助更多优秀的IP获得跨平台、多形态的发展机会,通过新文创的方式让更多用户和年轻人,获得高品质的数字内容消费体验,并以*先进的技术手段保护好未成年人,避免不健康的消费沉迷。

我们将更加重视科技驱动力。几天前,我受邀在知乎提问,非常高兴看到很多网友针对基础科学的突破、产业互联网与消费互联网的融合创新,做了相当精彩的回答。过去,中国互联网与科技行业的创新,往往是“应用需求找技术支持”。未来,我相信会有越来越多创新来自“技术突破寻求产品落地”。腾讯正在不断引入各领域的优秀科学家,也希望通过加大基础科学投入、建立公司技术委员会等措施,尽可能为科研工作者和技术人员创造更好的工作氛围和团队文化,真正让“科技创新”与“数字工匠精神”成为更多人追求的方向。

我们有理由期待,数字时代能够实现工业时代难以达到的工艺水平,创造出更高品质、更为独特的产品与服务。当然,腾讯并不是要到各行各业的跑道上去赛跑争**,而是要立足做好“助手”,帮助实体产业在各自的赛道上成长出更多的世界**。

过去一年,我们看到很多用户与合作伙伴通过各种渠道对腾讯的发展提出了意见和建议。在此,我要向关心腾讯发展的每一位朋友道一声感谢。你们的期待和鼓励,是腾讯多年来不断迭代进步的重要动力。

希望我们一起携手努力!谢谢大家!

2018年10月31日

转自腾讯科技

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug CandidatesWEDNESDAY, OCTOBER 30, 2019Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ProQinase, an early stage drug-discovery company, recently acquired by Malvern/PA-based Reaction Biology Corp., today announced that they have established an array of advanced biochemical and cellular assays to characterize epitranscriptomic-directed compounds.“Establishing tailored target engagement, cell biology, phenotypic, and in-vivo assays to evaluate compounds originating from our three most advanced epitranscriptomic programs in parallel is a crucial next step to develop our broad pipeline towards the clinic,” said Dr. Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. “By pursuing the full range of the reader-writer-eraser continuum, we are able to focus on targets with the most compelling links to disease and advance those programs in tandem.”“Combining our high proficiency in providing customized solutions as early stage drug-discovery services, including tailor-made biochemical and cell-based assays, with Gotham’s expertise in epitranscriptomics, we were able to establish in a very short time a set of customized enzymatic and cellular assays for compounds addressing three different mRNA-modifying targets,” said Dr. Sebastian Dempe, Chief Executive Officer of ProQinase. “We look forward to supporting Gotham as the company advances its programs into lead optimization and to continued work with the Gotham team assisting the company to advance its broad pipeline in a time-effective manner.”In addition to establishing a tailor-made profiling cascade for compounds from its three most advanced programs, Gotham has also made progress in strengthening its drug discovery engine and developing its candidate base. Gotham previously completed the gene-to-lead phase for its drug discovery project targeting the METTL3/METTL14 complex and established a robust discovery process as a platform for future projects. The company has also generated a library of high-quality compounds tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space. This library includes a collection of over 2,000 analogues covering over 80 distinct chemotypes that will be used to further accelerate Gotham’s drug discovery efforts as it expands its pipeline.The original link:https://www.pharmafocusasia.com/news/gotham-therapeutics-establishes-advanced-oncology-profiling-cascade-with-proqinase-to-progress-its-portfolio-of-epitranscriptomic-drug-candidates2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentTUESDAY, OCTOBER 29, 2019Gilead Sciences Inc. and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development2019 Asia-pacific pharma IP Leader Summit:http://en.zenseegroup.com/p/510934/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology PlatformMONDAY, OCTOBER 28, 2019HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.Published preclinical studies have demonstrated the use of HistoIndex's fully quantifiable Second Harmonic Generation (SHG) technology as a highly accurate stain-free method that can monitor the efficacy of various therapeutic agents, by quantifying more than 450 NASH-associated parameters in fibrosis, inflammation, ballooning and steatosis. The information of these NASH-associated parameters gathered from the entire liver tissue, provides comprehensive insights on the mechanism of action of the therapeutic agent.  As a drug discovery tool, HistoIndex's SHG-enabled digital pathology platform will allow pharmaceutical and biotech companies to select promising lead candidates for further optimization and make informed decisions in the management of their NASH drug development pipeline.In addition to ongoing NASH clinical trials, HistoIndex is currently involved in multiple preclinical studies, most of which are conducted by major pharmaceutical and biotech companies, medical universities, CROs and research agencies. Notably, HistoIndex has recently entered into a collaboration with the A*STAR's Genome Institute of Singapore (GIS) to validate their in vivo and in vitro NASH models based on Asian-centric clinical data. Says Professor Patrick Tan, Executive Director of the Genome Institute of Singapore (GIS), "At GIS, we conduct our preclinical studies on fatty liver involving data from animal models based on patient-derived transcriptomic data. This has a high translational potential as it helps us to pinpoint new therapeutic targets and their validation. Therefore, using a fully quantitative, reliable and objective pathological evaluation such as HistoIndex's AI-based digital pathology platform is essential to the success of our efforts in therapeutic target discovery."HistoIndex is also a partner with globally-renowned CRO, WuXi Apptec, in advancing their NASH preclinical programs with advanced R&D and smart imaging analysis capabilities. Published study data will be available for discussions during networking opportunities throughout AASLD's The Liver Meeting® in November 2019.  "We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development," says Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. "Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly."information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/histoindex-announces-global-partnerships-to-expand-ai-based-digital-pathology-platform2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. The Company is actively recruiting in Canada for its Phase 1/2 clinical trial of AVR-RD-02, which seeks to evaluate the safety and efficacy of the therapy in patients with Type 1 Gaucher disease.“Under the existing standard of care, patients with Gaucher disease are bound to a lifelong infusion schedule of enzyme replacement therapies, and still experience painful and progressive symptoms such as debilitating musculoskeletal pain and fatigue,” said Birgitte Volck, MD, PhD, President of Research and Development at AVROBIO. “Orphan-drug designation recognizes the unmet need of populations with rare diseases like Gaucher where AVROBIO strives to transform lives by addressing the underlying cause of the disease with a single dose of gene therapy.”Orphan-drug designation is granted by the FDA to drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. Orphan-drug designation provides certain incentives, which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/avrobio-receives-orphan-drug-designation-from-the-us-fda-for-avrrd02-for-the-treatment-of-gaucher-disease2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the acquisition of Smith Therapeutics, a private biopharmaceutical company with a shared goal of targeting neuroinflammation to treat neurodegenerative disease. Smith Therapeutics’ Founder and Chief Executive Officer Philip Ashton-Rickardt, Ph.D., has joined the senior leadership team at AZTherapies as Senior Vice President of Immunology. Financial terms of the acquisition were not disclosed.Smith Therapeutics’ proprietary research platform focuses on the use of modified T cells to restore a healthy balance of inflammatory and regulatory cells in the brain. To date, Smith has successfully engineered immunosuppressive T regulatory (Treg) cells with Chimeric Antigen Receptors (CARs) targeting brain glial cells. Previous research has demonstrated the ability of Tregs to dampen microglial activity and reduce neuroinflammation in models of neurodegeneration, suggesting their potential utility in the treatment of diseases including Progressive Supranuclear Palsy (PSP), Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and others.“This acquisition represents a meaningful step forward for us as we continue to strengthen our leadership position in the development of therapies targeting neuroinflammation to stop or slow the progression of neurodegenerative diseases,” said David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies. “We are excited to be working with Philip as we add this cutting-edge technology to our portfolio of innovative programs. An esteemed immunologist and inventor of the technology, Philip brings unparalleled expertise to the company and we look forward to advancing this CAR-Treg program further into IND-enabling studies and into clinical development as rapidly as possible.”Dr. Ashton-Rickardt commented on the acquisition and his appointment: “Our shared rationale of targeting neuroinflammation as the root cause of neurodegenerative disease makes this acquisition a great strategic fit for us. With AZTherapies’ expertise in drug development and clinical trial execution, we believe that together, we are well positioned to advance our CAR-Treg technology and fundamentally change neurodegenerative disease progression.”Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago. His work has been recognized by his peers through the award of tenure from The University of Chicago and by his fellow citizens as a recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton. He has published more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology), has served as an editor for several academic journals, and has been a member of grant review boards globally. Dr. Ashton-Rickardt received a B.Sc. in Biochemistry from the University of London, King’s College with honors, a Ph.D. in Molecular Biology from the University of Edinburgh, and completed post-doctoral work at the University of Edinburgh and the Massachusetts Institute of Technology in Molecular Biology and Molecular Immunology, respectively.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/aztherapies-strengthens-neuroinflammation-targeted-pipeline-through-acquisition-of-smith-therapeutics2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

About Us
Contact Us
Zensee_Daystar online